ArticleInternational journal of hepatology2026
Association of the STAT3 rs1053004 Polymorphism With Hepatocellular Carcinoma in Iraqi Patients With Hepatitis B.
Article in International journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of the STAT3 rs1053004 Polymorphism With Hepatocellular Carcinoma in Iraqi Patients With Hepatitis B.International journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: HCC is still one of the main causes of cancer-related fatalities despite years of intensive attempts to prevent it. One known risk factor is a persistent hepatitis B virus (HBV) infection. Previous studies have indicated a contribution of the STAT3 signaling pathway to carcinogenesis through inflammation mechanisms. In this study, we tried to explore the correlation between STAT3 rs1053004 polymorphism and HCC occurrence in people with HBV infection in Iraq. Methods: A case-control approach was applied with the inclusion of 80 patients with HCC due to HBV infection, 80 patients with CHB, and 80 healthy controls. The study was based on genotyping of the STAT3 rs1053004 polymorphism by a TaqMan SNP genotyping assay. Multivariate logistic regression analysis was used to assess the genetic association with disease risk, adjusting for potential confounding factors. Results: The three groups under study had significantly different genotype and allele distributions ( Conclusion: STAT3 rs1053004 polymorphism plays a significant role in the development of HCC risk in people with HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.